Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


The Japanese Ministry of Health, Labor and Welfare has approved the use of pembrolizumab for the treatment of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy

Japan Approves Pembrolizumab for Urothelial Carcinoma

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses the potential for immunotherapy in penile cancer.

Dr. Sonpavde on the Potential for Immunotherapy in Penile Cancer

Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).

Reckamp Recounts Recent Lung Cancer Advances

Daniel E. Haggstrom, MD, discusses the developing area of immunotherapy combinations for patients with non-small cell lung cancer.

Various Immunotherapy Combinations Continue to Be Explored in NSCLC

The Future of Treatment for Nonmetastatic CRPC 

Nonmetastatic CRPC: The Changing Landscape of Treatment   

Enzalutamide in the Context of Nonmetastatic CRPC 

Darolutamide's Role in Treating Nonmetastatic CRPC

MFS: A New Endpoint for Nonmetastatic CRPC  

Nonmetastatic CRPC: Considerations for Apalutamide 

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC 

The Value of AR-Targeted Therapy in CRPC 

Approaching the Treatment of Nonmetastatic CRPC 

Understanding Nonmetastatic CRPC: An Overview 

Treating Advanced Bladder Cancer in the Future

Practical Considerations With Checkpoint Inhibitors in Bladder Cancer

Immunotherapy in Second-Line Advanced Bladder Cancer

Monitoring for Treatment Response in Advanced Bladder Cancer

Frontline Immunotherapy in Advanced Bladder Cancer

First-Line Chemotherapy in Advanced Bladder Cancer

Immuno-Oncology

Immuno-Oncology | Specialty